Lucknow, December: A new drug for heart attack and stroke will soon be available in the market. The Council of Scientific and Industrial Research (CSIR) – Central Drug Research Institute (CDRI), Lucknow has tied up with UP based Mark Laboratories Pvt Ltd to encourage growth of pharma cluster in Uttar Pradesh.
Mark Laboratories Limited, a farm company operating in 13 other states of India including Uttar Pradesh had earlier signed agreement with CDRI for development of synthetic compound S007-867 as a modulator of blood clotting process.
Meanwhile, the technology of its manufacture has also been transferred on Friday.
The compound S007-867 is highly effective in the treatment of coronary and cerebral artery diseases, particularly as an inhibitor of collagen-induced platelet aggregation. The institute has recently obtained permission to start phase I clinical trials for the drug.
The risk of bleeding with this drug is extremely low as compared to other treatments currently available for coronary and cerebral artery diseases.
In animal experiments, this novel medicinal compound has shown superior antithrombotic properties with minimal bleeding compared to prevailing standards of care. The institute has also recently obtained permission to start phase I clinical trials for this drug.
On this occasion, CDRI Director Prof Tapas Kumar Kundu, said, โThis is a momentous moment for CSIR-CDRI, the country’s premier drug research institute. The technology for synthesis of this innovative medicinal compound has been successfully transferred to Mark Laboratories Ltd.
He said that he is hopeful that this compound will soon reach the market for human service.
He also mentioned that it will be very beneficial for the development of pharma cluster in Uttar Pradesh and will open new avenues for manufacturing of Made in India and indigenous affordable medicine in the country.
